Neurocrine BiosciencesLTS:0K6R +1.08%96 ROA % is 16.60% as of Mar. 2026, which is 184% above its 10-year median of 5.84. GuruFocus rates LTS:0K6R with a GF Score™ of 96/100 and a GF Value™ of $189.77 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 92.73% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Neurocrine Biosciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $792 Mil.
Neurocrine Biosciences's average Total Assets over the quarter that ended in Mar. 2026 was $4,769 Mil. Therefore, Neurocrine Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was 16.60%.
The historical rank and industry rank for Neurocrine Biosciences's ROA % or its related term are showing as below:
LTS:0K6R'
s ROA % Range Over the Past 10 Years
Min: -33.6 Med: 5.84 Max: 26.79
Current: 15.64
During the past 13 years, Neurocrine Biosciences's highest ROA % was 26.79%. The lowest was -33.60%. And the median was 5.84%.
LTS:0K6R's ROA % is ranked better than 92.73% of 1004
companies
in the Drug Manufacturers industry
Industry Median: 2.75
vs LTS:0K6R: 15.64
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's ROA % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Neurocrine Biosciences (LTS:0K6R) has a ROA % of 16.60% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Neurocrine Biosciences and its competitors. This is 184% above median its historical median of 5.84. According to the industry distribution chart, Neurocrine Biosciences ranks #73 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 7.3%.
Is Neurocrine Biosciences' ROA % too high?
Neurocrine Biosciences' current ROA % of 16.60% is 184% above median its 10-year median of 5.84. The Drug Manufacturers industry median ROA % is 2.75. Neurocrine Biosciences' value of 16.60% is 503.6% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #73 out of 1004 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' ROA % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #73 out of 1004 companies for ROA %. This places Neurocrine Biosciences in the top 7% of its industry — outperforming the majority of peers. The industry median ROA % is 2.75. Neurocrine Biosciences' value of 16.60% is 503.6% above this benchmark. While the company's 10-year median is 5.84 vs. the industry median of 2.75, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.75, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current ROA % of 16.60% is 503.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current ROA % is 16.60%, which is 184% above median its own 10-year median of 5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Modestly Undervalued. The stock's GF Value™ is $189.77, compared to a current price of $170.14 — trading 10.3% below its estimated fair value. The current ROA % is 16.60%, which is 184% above median its 10-year median of 5.84 and 503.6% above the Drug Manufacturers industry median of 2.75. Neurocrine Biosciences' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current ROA % is 16.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $170.14 is trading 10.3% below its estimated GF Value™ of $189.77.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for LTS:0K6R:
ROA %: 16.60% (184% above median its 10-year median of 5.84)
GF Value™: $189.77 vs. price of $170.14 (10.3% below fair value)
Industry Position: 503.6% above the Drug Manufacturers median (#73 of 1004)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
96GF Score
Get the complete analysis for LTS:0K6R
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 
